NCT00328926终止4 期
A Phase IV, Multicenter, Randomized, Double-blinded, Clinical Trial to Confirm the Efficacy of the 75 IU Dose of Luveris® vs. Placebo When Administered With Follitropin Alfa for Induction of Follicular Development and Pregnancy in Hypogonadotropic Hypogonadal Women With Profound LH Deficiency, as Defined by a Baseline LH Level <1.2 IU/L
适应症
干预措施
相关药物
试验速览
- 阶段
- 4 期
- 状态
- 终止
- 发起方
- EMD Serono
- 入组人数
- 11
- 试验地点
- 1
- 主要终点
- Time to Clinical Pregnancy
研究概览
简要总结
Sponsor has decided to discontinue Luveris® in the United States (US) due to level of customer demand for this product, and not due to any efficacy or safety concerns.
详细描述
To confirm the efficacy of the 75 IU dose of Luveris® compared to placebo when administered concomitantly with follitropin alfa for induction of clinical pregnancy in women with hypogonadotropic hypogonadism and profound LH deficiency (LH <1.2 IU/L), and to study the efficacy of a lower dose (25 IU) of Luveris® compared to placebo when administered concomitantly with follitropin alfa for induction of follicular development in women with hypogonadotropic hypogonadism and profound LH deficiency (LH <1.2 IU/L).
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Parallel
- 主要目的
- Treatment
- 盲法
- Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
入排标准
- 年龄范围
- 18 Years 至 40 Years（Adult）
- 性别
- Female
- 接受健康志愿者
- 否
入选标准
- •Be premenopausal, between 18 and 40 years of age inclusive on the day of consent
- •Have a clinical history of hypogonadotropic hypogonadism (World health organization [WHO] Group I type of anovulation) on the basis of congenital or acquired hypothalamic or pituitary endocrine dysfunction in the presence of qualifying screening laboratories
- •Have no prior treatment cycles with gonadotropins or gonadotropin releasing hormone (GnRH) (gonadotropin naïve)
- •Have discontinued estrogen-progesterone replacement therapy at least one month before the screening procedure
- •Have primary or secondary amenorrhea
- •Have a negative progestin challenge test performed during Screening
- •Have the following hormonal values in a centrally analyzed fasting blood sample, drawn within 6 weeks before initiation of treatment:
- •Follicle-Stimulating Hormone (FSH): less than (<)5 international unit per liter (IU/L)
- •Leutinizing hormone (LH): <1.2 IU/L (a second Baseline serum LH level will be repeated two weeks after the initial LH draw)
- •Prolactin: < 43.3 nanogram per milliliter (ng/mL) (<1040 milli-international unit per liter [mIU/L])
- •Thyroid Stimulating Hormone (TSH): <6.5 micro-international units per milliliter (mcIU/mL)
- •Free Thyroxin (T4): 0.8-1.8 nanogram per deciliter (ng/dL) (11-24 picomole per liter [pmol/L])
- •Testosterone: <1.0 ng/mL (<3.5 nanomole per liter [nmol/L])
- •Have an endovaginal pelvic ultrasound scan showing (i) no clinically significant uterine abnormality, (ii) no ovarian tumor or cyst, and (iii) less than or equal to (=<)13 small follicles (mean diameter =<10 milliliter [mm]) on the largest section through each ovary
- •Have a normal cervical pap smear within 6 months of the initial visit
- •Where indicated, have a normal or unchanged computed tomography (CT) scan or nuclear magnetic resonance (NMR) scan of the hypothalamic pituitary region on file
- •Have a body mass index (BMI) between 18.4 and 31.4 kilogram per square meter (kg/m^2)
- •Be willing and able to comply with the protocol for the duration of the study
- •Have given written informed consent prior to any study related procedure not part of normal medical care, with the understanding that consent may be withdrawn by the subject at any time without prejudice to her future medical care
排除标准
- •Any medical condition which in the judgment of the investigator may interfere with the absorption, distribution, metabolism or excretion of the drug
- •Any pre-existing medical condition which would compromise the subject's ability to conceive in vivo or to successfully complete a pregnancy
- •Ongoing pregnancy
- •Clinically important systemic disease (example: insulin-dependent diabetes mellitus, epilepsy, serious migraine, intermittent purpura, hepatic, renal or cardiovascular disease, serious corticoid-dependent asthma)
- •Known infection with human immunodeficiency virus (HIV), Hepatitis B or C
- •Ovarian enlargement or cyst of unknown etiology
- •Abnormal gynecological bleeding of undetermined origin
- •Previous or current hormone dependent tumor
- •Known active substance abuse or eating disorder
- •Known central nervous system (CNS) Lesions: In cases where hypogonadotropic hypogonadism (HH) is secondary to a CNS lesion or its treatment
- •Exercise program exceeding 10 hours per week
- •Is planning to undergo in vitro fertilization, intracytoplasmic sperm injection or another assisted reproductive technology (ART) procedure, other than intrauterine insemination, in the course of a study treatment cycle
- •Currently undergoing treatment with psychotropic medication or with any other medication known to interfere with normal reproductive function (example: neuroleptics, dopamine antagonists)
研究组 & 干预措施
Luveris® 75 IU
Active Comparator
干预措施: Luveris® 75 IU (Drug)
Luveris® 75 IU
Active Comparator
干预措施: Recombinant human follicle stimulating hormone (r-hFSH) (Drug)
Luveris® 75 IU
Active Comparator
干预措施: Recombinant human chorionic gonadotropin (r-hCG) (Drug)
Luveris® 25 IU
Active Comparator
干预措施: Luveris® 25 IU (Drug)
Luveris® 25 IU
Active Comparator
干预措施: Recombinant human follicle stimulating hormone (r-hFSH) (Drug)
Luveris® 25 IU
Active Comparator
干预措施: Recombinant human chorionic gonadotropin (r-hCG) (Drug)
Placebo
Placebo Comparator
干预措施: Placebo (Drug)
Placebo
Placebo Comparator
干预措施: Recombinant human follicle stimulating hormone (r-hFSH) (Drug)
Placebo
Placebo Comparator
干预措施: Recombinant human chorionic gonadotropin (r-hCG) (Drug)
结局指标
主要结局
Time to Clinical Pregnancy
时间窗: Stimulation Day 1 up to clinical pregnancy (Day 35-42 post r-hCG administration day [end of stimulation cycle {approximately 21 days}])
Clinical pregnancy was defined as the presence of one or more fetal sac with fetal heart activity on the Day 35-42 post r-hCG ultrasound examination.
次要结局
- Percentage of Participants With Cumulative Clinical Pregnancy(Day 35-42 post r-hCG administration day (end of stimulation cycle [approximately 21 days]))
- Percentage of Participants With Cumulative Ovulation(Recombinant human chorionic gonadotropin (r-hCG) administration day (end of stimulation cycle [approximately 21 days]))
研究者
研究点 (1)
Loading locations...
相似试验
已完成
2 期
A Study of Rilematovir (JNJ-53718678) in Adult Outpatients with Respiratory Syncytial Virus (RSV) InfectioJPRN-jRCT2031210527akama Takahiro5
已完成
不适用
Evaluation of Treatment Response and Quality of Life of Esomeprazole for Reflux Esophagitis PatientsReflux EsophagitisJPRN-UMIN000014449agoya University Graduate School of Medicine, Department of Gastroentelorogy and Hepatology3
终止
1 期
Atacicept in Lupus Nephritis Patients Taking Stable Regimen of Mycophenolate MofetilLupus NephritisNCT01369628EMD Serono1
已完成
2 期
A Multicenter, Single Arm, Open-label Study to Investigate the Efficacy and Safety of Ravagalimab (ABBV-323) in Subjects with Moderate to Severe Ulcerative Colitis Who Failed Prior TherapyIBDNL-OMON49261AbbVie B.V.6
已完成
不适用
A Phase 1b, Multicenter, Open-Label Study to Determine the Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy of ABBV-368 plus Tilsotolimod and Other Therapy Combinations in Subjects with Recurrent/Metastatic Head and Neck Squamous Cell CarcinomaNL-OMON49382AbbVie B.V.2